Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

  • Verkindre C
  • Fukuchi Y
  • Flémale A
 et al. 
  • 50

    Readers

    Mendeley users who have this article in their library.
  • 63

    Citations

    Citations of this article.

Abstract

NVA237 is a once-daily inhaled long-acting muscarinic antagonist in development for the treatment of COPD. This randomized, double-blind, placebo-controlled, four-period, incomplete block crossover study, with open-label active comparator (tiotropium), assessed the efficacy and safety of NVA237. Patients (≥40 years; smoking history ≥10 pack-years) with stable moderate-to-severe COPD (post-bronchodilator FEV1≥ 30% and

Author-supplied keywords

  • COPD
  • Efficacy
  • Long-acting muscarinic antagonist
  • NVA237
  • Safety
  • Tiotropium

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free